Search research articles
Contact Us
Filters
Showing results (111-120 of 173) with videos related to
Page
of 18
Sort By:
Breast Care (Basel, Switzerland)
|
February 26, 2019
Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy
Cornelia Liedtke, Dennis Görlich, Ingo Bauerfeind, et al.
Breast Cancer Research and Treatment
|
June 26, 2015
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
Sibylle Loibl, Christian Jackisch, Bianca Lederer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2012
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, et al.
Eclinicalmedicine
|
December 2, 2022
Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer
Toralf Reimer, Angrit Stachs, Kristina Veselinovic, et al.
The Lancet. Oncology
|
January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Michael Untch, Sibylle Loibl, Joachim Bischoff, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2017
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Sherko Kümmel, Stefan Paepke, Jens Huober, et al.
Breast Cancer Research : BCR
|
September 18, 2009
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani, Sibylle Loibl, Berit M Müller, et al.
Annals of Surgical Oncology
|
April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)
Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2020
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials
Gustavo Werutsky, Michael Untch, Claus Hanusch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Response-guided neoadjuvant chemotherapy for breast cancer
Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 173) with videos related to
Sort By:
Page
of 18
Breast Care (Basel, Switzerland)
|
February 26, 2019
Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy
Cornelia Liedtke, Dennis Görlich, Ingo Bauerfeind, et al.
Breast Cancer Research and Treatment
|
June 26, 2015
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
Sibylle Loibl, Christian Jackisch, Bianca Lederer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2012
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, et al.
Eclinicalmedicine
|
December 2, 2022
Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer
Toralf Reimer, Angrit Stachs, Kristina Veselinovic, et al.
The Lancet. Oncology
|
January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Michael Untch, Sibylle Loibl, Joachim Bischoff, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2017
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Sherko Kümmel, Stefan Paepke, Jens Huober, et al.
Breast Cancer Research : BCR
|
September 18, 2009
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani, Sibylle Loibl, Berit M Müller, et al.
Annals of Surgical Oncology
|
April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)
Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2020
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials
Gustavo Werutsky, Michael Untch, Claus Hanusch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Response-guided neoadjuvant chemotherapy for breast cancer
Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, et al.
Page
of 18